Enzymes that hydrolyze beta-lactams and cephalosporin antibiotics are called beta-lactamases, and their production by bacteria is the most common way that bacteria become antibiotic-resistant. The Zn(II)- containing beta-lactamases constitute an ever-growing and troubling class of beta-lactamases which contain 2 moles of Zn(II) per mole of enzyme, hydrolyze all known penicillin and cephalosporin antibiotics, are not inhibited by clavulanic acid, and have no known inhibitor of activity. The long-term objective of the proposed research is the rational design and preparation of irreversible inhibitors of the Zn(II)-containing beta-lactamases. Given the apparent structural and mechanistic differences among the metallo-beta-lactamases, this objective can only be realized after detailed characterization of a member from each distinct subclass of metallo-beta-lactamases. Similarities between the enzymes can then be identified and exploited for the rational design of an inhibitor. This proposal involves the study of the structurally-distinct, biomedically-important beta- lactamase (L1) from X maltophilia.
The specific aims of this proposed research are: (1) detailed structural characterization of the metal binding sites of metal-substituted forms of the X. maltophilia beta- lactamase using spectroscopic, mutagenesis, and binding studies, (2) elucidation of the mode of action of the enzyme with several penicillin and cephalosporin antibiotics using steady-state and pre-steady state kinetics studies, (3) identification of the overall reaction mechanism used by Ll and of any stable reaction intermediates using mathematical simulations of kinetics rate profiles and results from biochemical studies, (4) integration of structural and mechanistic results to identify key aspects of the enzyme that can be targeted for the development of novel reaction- or structure-based inhibitors, and (5) examination of the possible inhibition properties of compounds, when once hydrolyzed produce reactive, exocyclic methylene groups. It is hoped that this novel integration of kinetics, biochemical, simulations, and spectroscopic studies can be used as a general strategy for the preparation of new antimicrobial agents and a better way to combat the ever-increasing prevalence of antibiotic resistance in bacteria.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29AI040052-05
Application #
6475707
Study Section
Metallobiochemistry Study Section (BMT)
Program Officer
Preusch, Peter C
Project Start
1997-12-01
Project End
2002-11-30
Budget Start
2001-12-01
Budget End
2002-11-30
Support Year
5
Fiscal Year
2002
Total Cost
$62,294
Indirect Cost
Name
Miami University Oxford
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
041065129
City
Oxford
State
OH
Country
United States
Zip Code
45056
Holdorf, Meghan M; Bennett, Brian; Crowder, Michael W et al. (2008) Spectroscopic studies on Arabidopsis ETHE1, a glyoxalase II-like protein. J Inorg Biochem 102:1825-30
Sharma, Narayan; Hu, Zhenxin; Crowder, Michael W et al. (2008) Conformational changes in the metallo-beta-lactamase ImiS during the catalytic reaction: an EPR spectrokinetic study of Co(II)-spin label interactions. J Am Chem Soc 130:8215-22
Carenbauer, Anne L; Garrity, James D; Periyannan, Gopal et al. (2002) Probing substrate binding to metallo-beta-lactamase L1 from Stenotrophomonas maltophilia by using site-directed mutagenesis. BMC Biochem 3:4
Crowder, M W; Yang, K W; Carenbauer, A L et al. (2001) The problem of a solvent exposable disulfide when preparing Co(II)-substituted metallo-beta-lactamase L1 from Stenotrophomonas maltophilia. J Biol Inorg Chem 6:91-9
Yanchak, M P; Taylor, R A; Crowder, M W (2000) Mutational analysis of metallo-beta-lactamase CcrA from Bacteroides fragilis. Biochemistry 39:11330-9
Brandt, J J; Chatwood, L L; Crowder, M W (2000) Analysis of three overexpression systems for VanX, the Zinc(II) dipeptidase required for high-level vancomycin resistance in bacteria. Protein Expr Purif 20:300-7
Yang, K W; Brandt, J J; Chatwood, L L et al. (2000) Phosphonamidate and phosphothioate dipeptides as potential inhibitors of VanX. Bioorg Med Chem Lett 10:1085-7
McManus-Munoz, S; Crowder, M W (1999) Kinetic mechanism of metallo-beta-lactamase L1 from Stenotrophomonas maltophilia. Biochemistry 38:1547-53
Brandt, J J; Chatwood, L L; Yang, K W et al. (1999) Continuous assay for VanX, the D-alanyl-D-alanine dipeptidase required for high-level vancomycin resistance. Anal Biochem 272:94-9
Yang, K W; Crowder, M W (1999) Inhibition studies on the metallo-beta-lactamase L1 from Stenotrophomonas maltophilia. Arch Biochem Biophys 368:1-6